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Abstract
Objective—To examine the cost-effectiveness of the HITIDES intervention.
Design—Randomized controlled effectiveness and implementation trial comparing depression 
collaborative care with enhanced usual care.
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Setting—Three Veterans Health Administration (VHA) HIV clinics in the Southern US.
Subjects—249 HIV-infected patients completed the baseline interview; 123 were randomized to 
the intervention and 126 to usual care.
Intervention—HITIDES consisted of an off-site HIV depression care team that delivered up to 
12 months of collaborative care. The intervention used a stepped-care model for depression 
treatment and specific recommendations were based on the Texas Medication Algorithm Project 
and the VA/Department of Defense Depression Treatment Guidelines.
Main outcome measure(s)—Quality-adjusted life years (QALYs) were calculated using the 
12-Item Short Form Health Survey, the Quality of Well Being Scale, and by converting 
depression-free days to QALYs. The base case analysis used outpatient, pharmacy, patient, and 
intervention costs. Cost-effectiveness was calculated using incremental cost effectiveness ratios 
(ICERs) and net health benefit (NHB). ICER distributions were generated using nonparametric 
bootstrap with replacement sampling.
Results—The HITIDES intervention was more effective and cost-saving compared to usual care 
in 78% of bootstrapped samples. The intervention NHB was positive and therefore deemed cost-
effective using an ICER threshold of $50,000/QALY.
Conclusions—In HIV clinic settings this intervention was more effective and cost-saving 
compared to usual care. Implementation of off-site depression collaborative care programs in 
specialty care settings may be a strategy that not only improves outcomes for patients, but also 
maximizes the efficient use of limited healthcare resources.
INTRODUCTION
Depression is the single most common mental health condition seen in non-mental health 
settings. [1] Collaborative care for depression is effective [2–13] and cost-effective in adult 
primary care, [14–21] but many patients are seen outside primary care. It is less clear 
whether collaborative care for depression is effective in specialty care, few studies have 
been completed on this topic to date.[22, 23] Even more unclear is whether collaborative 
care for depression is cost-effective outside of primary care, because the cost profiles of 
specialty care providers and the services they provide are significantly different from those 
seen in primary care.
We chose Human Immunodeficiency Virus (HIV) as our test case because it is similar to a 
primary care setting in that many HIV providers often provide whole person care, not just 
HIV care. Also, depression is associated with non-adherence to HIV medication regimens 
and decreased immune functioning which can lead to accelerated HIV progression and 
increased risk of mortality.[24–33] Because depression can be effectively managed, it is a 
modifiable risk factor for the progression of HIV.[34–36] We chose the Veterans Health 
Administration (VHA) because it is the largest provider of HIV care in the nation[37] and it 
has a long history of mental health delivery innovation. As previously reported, the HIV 
Translating Initiatives for Depression Into Effective Solutions (HITIDES) intervention 
described in more detail below resulted in a significant increase in depression-free days and 
decrease in HIV symptom severity compared to usual care.[22] To our knowledge this is the 
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first cost-effectiveness analysis of a collaborative care intervention for depression set in a 
specialty physical healthcare setting.
METHODS
STUDY SETTING AND ENROLLMENT PROCEDURES
The intervention, methods, and clinical outcomes of the HITIDES study have been 
described in detail elsewhere.[22] To summarize, the HITIDES study was a randomized 
controlled implementation and effectiveness trial comparing depression collaborative care 
with enhanced usual care in three VA HIV specialty clinics.[38] Depression screening was 
implemented as part of usual care at all sites.[22]
USUAL CARE DESCRIPTION
All clinic site healthcare providers participating in the study received one hour of training in 
the detection and management of depression in patients with HIV and were also instructed 
in referral procedures for specialty mental healthcare at their site. These procedures included 
the suggestion of at least one failed depression treatment trial before referral. Usual care 
consisted of depression treatment by HIV or mental health clinicians without involvement 
from the HITIDES depression care team.
HITIDES INTERVENTION DESCRIPTION
A more detailed description of the intervention has been published elsewhere.[22] The 
HITIDES intervention involved collaboration between on-site HIV providers and an off-site 
HITIDES depression team comprised of a registered nurse depression care manager (DCM), 
clinical pharmacist, and psychiatrist (J.M.P). The HITIDES depression care support team 
was located off-site at the Central Arkansas Veterans Healthcare System in Little Rock, AR 
and met weekly or as needed either in-person or via telephone to discuss patients who were 
not responding to current depression treatment. All clinical communications with care 
providers took place in the electronic medical record progress notes. The DCM was solely 
responsible for communication with patients which was done exclusively via telephone. The 
HITIDES care team provided treatment suggestions to the clinicians responsible for direct 
patient care; all treatment decisions were ultimately left to on-site treatment providers.
Patients received the following intervention components from the DCM via a telephone 
encounter: participant education and activation,[39] assessment of treatment barriers and 
possible resolutions, depression symptom and treatment monitoring, substance abuse 
monitoring, and instruction in self-management (e.g., encouraging patients to exercise and 
participate in social activities).[4, 40] The DCM used standardized instruction scripts, which 
were supported by the Web-based decision support system NetDSS (available at https://
www.netdss.net) during these telephone encounters.[41] The intervention used a stepped-
care model for depression treatment[2] and specific treatment recommendations were based 
on the Texas Medication Algorithm Project[42] and the VA/Department of Defense 
Depression Treatment Guidelines.[43]
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Baseline, 6- and 12-month data were collected by telephone interviewers who were blinded 
to treatment assignment and used computer-assisted assessments. At baseline, 
demographics, depression history, and chronic physical health conditions were measured 
using the Depression Outcomes Module.[44, 45] Mental health comorbidity was measured 
using the Mini International Neuropsychiatric Interview.[46, 47] Acceptability of 
antidepressant treatment was measured using an item developed for the Quality 
Improvement for Depression studies.[6, 48] Follow-up data-collection interviews were 
completed for 226/249 participants (90.8%) at 6 months and 215/249 (86.3%) at 12 months.
Depression-free days (DFDs) were calculated from the 20-item Symptom Checklist 
(SCL-20).[49] SCL-20≤0.5 was considered depression-free (1.0) and ≥2.0 was considered 
fully symptomatic (0.0) and scores in between were assigned a linear proportional value 
between 1.0 and 0.0. Disease-specific DFD-derived quality-adjusted life years (QALYs) 
were calculated by assigning 0.6 (traditional) or 0.8 (conservative) for patients who were 
fully symptomatic (SCL-20 ≥ 2.0), 1.0 for patients that were asymptomatic (SCL-20 ≤ 0.5), 
and assigning a linear proportional value for values in between. Therefore, 0.4 (traditional) 
and 0.2 (conservative) corresponded to the potential improvement in QALYs from fully 
depressed to fully asymptomatic. DFDs and DFD QALYs were calculated using area under 
the curve calculations of baseline, 6-month, and 12-month data.[50, 51] Generic QALYs 
were calculated using the SF-12 standard gamble to QALY conversion formula[52] and the 
QWB scale.[53, 54]
Intervention costs, healthcare expenditures, and patient costs were collected to assess the 
cost of the intervention from a societal perspective. Intervention costs included both fixed 
and variable costs. We included only DCM training as a net fixed intervention cost because 
the other fixed intervention costs were attributed to participants in both the intervention and 
usual care groups. Variable intervention costs included the time spent by intervention 
personnel delivering the intervention (e.g. time spent preparing and delivering the 
intervention, entering progress notes into the medical record, and attending intervention 
team meetings). These costs were calculated separately for the DCM, clinical pharmacist, 
and psychiatrist based on an hourly rate calculated from their respective VA salaries and 
fringe costs. Total intervention costs were estimated at $557 per intervention participant 
($68,503/123).
Healthcare expenditures were assessed using VA Decision Support System data. This 
system uses an activity-based costing allocation method and includes fixed direct, variable 
direct, and fixed indirect costs. While the cost estimates have not been validated via micro-
costing, DSS provides a useful proxy for encounter cost that is helpful to researchers. 
Outpatient expenditures for the base case analysis were organized in the following groups by 
clinic type (i.e., primary stop code): primary care, infectious disease, mental health, 
substance abuse, other medical specialty, and ancillary (including laboratory orders and 
radiography). Outpatient medication data were divided into HIV-related, depression-related, 
and other. Inpatient encounter data were used for secondary cost per QALY analyses. 
Patient travel and time expenditures were calculated based on self-reported time spent at 6- 
and 12-month follow-up interviews and income information collected at baseline. 
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Expenditures were not discounted because of the relatively short 12-month time horizon of 
the study.
STATISTICAL ANALYSIS
We utilized an intent-to-treat analysis at the patient level. We performed a power calculation 
assuming an 11% difference in the percentage of responders between intervention and usual 
care using a 1-tailed t test (α = .05). A sample size of 280 (140 subjects per arm) would 
provide 74% power. Independent variables with missing values were imputed using multiple 
imputation methods.[55] Owing to the large number of available covariates and the use of 
multiple imputation methods, only those covariates found to significantly predict dependent 
variables at p<0.10 in bivariate analyses were included in multivariate analyses. After model 
specification was finalized, healthcare costs for the year prior to patient baseline assessment 
were added as a covariate to expenditure models.
Due to skewness from several high cost outliers the expenditure outcomes were non-
normally distributed, so generalized linear models (GLMs) were utilized.[56] We ran 7 
GLMs with normal, gamma, or inverse normal distributions and identity, logarithm, or 
square root link functions using a consistent specification of independent variables. The 
GLM regression with a gamma distribution and identity link function fit the expenditure 
data most appropriately. Using a similar procedure, the GLM regression with an inverse 
normal distribution and log link fit the DFD QALY data best, while gamma with identity 
link was used for both SF-12 and QWB derived QALYs.
Based on the coefficients from the GLM regressions for the specified independent variables 
and the covariate values for each participant, we calculated two predicted expenditures for 
each participant to determine the incremental treatment effect on costs.[57] The first 
expenditure prediction was if the participant had been randomized to the intervention 
(factual for intervention patients and counterfactual for usual care), and the second 
expenditure prediction was as if the participant had been randomized to usual care 
(counterfactual for intervention patients and factual for usual care). The difference between 
these two expenditure predictions represented the incremental effect of the intervention on 
expenditures for a particular participant because all covariate effects were identical for the 
two estimates for a given patient. We then averaged the difference between the two 
predicted values for each participant and across all participants to generate an incremental 
effect in the entire sample.
The point estimate of the original sample will be used for means [58]; however, typical 
standard error estimation methods do not apply to incremental cost-effectiveness ratios 
(ICERs) for two reasons. First, the possibility of having zero or near zero denominators is 
non-negligible. Second, expenditure and effectiveness estimates are rarely independent.[58] 
Therefore, we ran 1000 replications of nonparametric bootstrap with replacement model to 
generate an empirical joint distribution of incremental expenditures and QALYs.[58, 59] We 
then constructed acceptability curves representing the probability of falling below ICER 
thresholds ranging from 0 to $100,000 per QALY for each clinical outcome: DFD-derived 
QALYs (0.4 [traditional] and 0.2 [conservative]), SF-12 standard gamble QALYs, and 
QWB-SA QALYs.[60]
Painter et al. Page 5
















In addition, we calculated the net health benefit (NHB) as suggested by Stinnett and 
Mullahy[61] to assist in the interpretation of [61] a negative (ICER). [58] NHB is calculated 
by dividing the marginal cost of the program by a cost-effectiveness threshold (e.g. $50,000/
QALY) and subtracting the result from the marginal effectiveness of the program (e.g. 
QALY difference). If the NHB is positive then the intervention is deemed cost-effective 
compared to the threshold used and should be selected for implementation. Otherwise, more 
health improvements could be attained by forgoing the intervention and investing in 
programs that are at least marginally cost-effective.
Results
Baseline sociodemographic, clinical, and depression-related variables are presented in Table 
1. In general, patients were middle-aged, predominantly African-American, single, males 
with high levels of physical and mental health comorbidity in addition to moderate HIV 
symptoms. The only group differences at baseline were intervention patients had lower 
QWB-SA scores (0.44 vs. 0.49, p<0.01) and higher physical health comorbidity scores (3.8 
vs. 3.2, p<0.05).
Table 2 summarizes intervention and healthcare costs incurred by patients in the 
intervention and usual care groups. Healthcare costs were broken into outpatient (e.g. 
primary care, infectious disease, mental health, etc.) and pharmacy costs (HIV-related, 
depression-related, and other). The only statistically significant unadjusted difference in 
healthcare costs either before or after the intervention was higher post-intervention 
infectious disease outpatient costs for the intervention group ($3427 vs. $2585), indicating 
that intervention patients had more infectious disease visits than usual care patients. Total 
unadjusted healthcare expenditures increased an average $1150 for usual care patients and 
decreased $840 for intervention patients. After adjustment for case mix variables the overall 
intervention was cost saving, specifically including outpatient and pharmacy costs resulted 
in cost savings of $1368 (p<0.01) (Table 3). When inpatient costs were added for a 
secondary analysis the cost savings for the intervention was $534, but no longer statistically 
significant. Inpatient costs were included in a secondary analysis because of the generally 
highly skewed distribution for these costs; this approach is consistent with the literature.[17–
19, 62, 63]
As reported previously, the intervention resulted in 19.3 (p<0.01) additional DFDs over 
usual care.[22] DFD QALYs were calculated by varying the QALY estimate associated with 
depression improving from fully depressed to fully asymptomatic (0.2 [traditional] to 0.4 
[conservative]). Using the most commonly reported DFD to QALY conversion (DFD 0.4 
[traditional]) resulted in 0.020 incremental QALYs and the more conservative approach 
(DFD 0.2 [conservative]) resulted in 0.011 incremental QALYs for the intervention in the 
original sample (Table 3 [case mix variables are listed in the table notes]). We also 
calculated incremental generic QALYs using SF-12 standard gamble (0.010 greater for the 
intervention) and the QWB-SA (0.009 greater for the intervention). Although the 
intervention resulted in significantly more DFDs none of the QALY measures (DFD-derived 
or generic) were statistically different between the intervention and usual care group. This 
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was not unexpected as the findings of the clinical effectiveness trial note there were 
significant differences at 6-month follow-up but not at 12-months.[22]
All mean ICERs taken from the original sample were negative (Table 3). Each of the NHB 
calculations using the $50,000/QALY threshold were positive for the intervention ranging 
from 0.037 QALYs for the QWB-SA QALYs to 0.048 QALYs for the DFD 0.4 to QALY 
conversion (Table 3). NHB analysis of the disease-specific DFD measure was also positive 
further supporting the cost-effectiveness of the intervention (156 additional DFDs).
Figure 1 gives the ICER distribution for the bootstrapped sample. Using the $50,000/QALY 
threshold, the base case analysis is cost-effective for 97% of the samples. Treatments that 
show ICERs less than $20,000/QALY are typically recommended for rapid dissemination 
into healthcare systems.[62] In our base case analysis, there is a 96.4% probability that the 
HITIDES intervention will cost less than $20,000/QALY and 77.8% probability that it will 
be cost saving. The acceptability curves for all four QALY measures are presented in Figure 
2 and the probability of being less than $50,000/QALY varies between 82–97%, depending 
on the QALY measure.
Discussion
The HITIDES intervention demonstrated improved outcomes and decreased costs compared 
to usual care over one year. Whereas depression and HIV symptom severity differences 
were statistically significant at 6-months, the QALY differences over 12-months were not. 
As Glick notes however, the lack of significant QALY differences represents “‘absence of 
evidence of a difference’ and not ‘evidence of absence of a difference’”.[64] For this reason, 
healthcare economists recommend evaluating the joint distribution of cost and effectiveness 
(e.g., incremental cost-effectiveness plane or acceptability curve) in order to identify 
situations where the examination of clinical effect and cost simultaneously indicates clear 
advantages for one intervention over another.[64–66] As evidenced by our bootstrapped 
sample, despite the small QALY difference, the intervention was cost-effective in 97% of 
replications.
Cost per QALY estimates for collaborative depression care in non-veteran populations range 
from $3,303/QALY to $67,225/QALY adjusted to 2013 dollars and using only outpatient 
costs.[19, 20, 49, 63, 67] In the VA, cost per quality estimates range from $67,965/QALY to 
$103,319/QALY, adjusted to 2013 dollars.[17, 68] These cost per QALY estimates indicate 
that the collaborative care interventions cost more and resulted in better outcomes than usual 
care.
Other studies have examined subsamples of patients with depression.[19] Katon et al found 
that a multi-condition collaborative treatment program for depression, diabetes, and 
coronary heart disease was both effective (114 additional DFDs, 0.335 QALYS over a two 
year period) and cost-saving.[69] In another subgroup of patients with depression and 
diabetes, collaborative care was associated with substantially lower non-mental health 
medication and outpatient costs and cost per QALY ratios ranged from $261 to $524 per 
QALY (2013 dollars).[62] These findings of cost-effective or cost-savings interventions in 
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complex primary care patients suggests that collaborative care interventions may be 
particularly cost-effective for comorbid high cost patients. This situation is especially true in 
the HIV clinic where the HITIDES intervention was implemented. Total outpatient and 
pharmacy costs averaged $25,381 in the year prior to the intervention; this is substantially 
higher than that seen in the multi-condition cohort ($10,026).
The cost savings associated with the HITIDES intervention appears to be attributable to 
lower HIV medication costs and ancillary (e.g. laboratory, radiography, etc.) costs. Couple 
this finding with the fact that the intervention group had more HIV clinic visits and lower 
HIV symptom severity[22] and the interpretation of these findings could be that HIV 
symptoms were better controlled in intervention patients requiring less expensive HIV 
medication and laboratory monitoring. Of note, mental health costs are not significantly 
different between the two groups before or after the intervention signifying no substitution 
for mental health care by the intervention. The implication of this finding is that a wider roll-
out of this intervention in VA HIV clinics could result in improved outcomes and cost 
savings. Further, given the demographic similarity between VA and non-VA HIV clinics,
[70] similar results may be possible in non-VA HIV clinic settings.
Since the NHB of the HITIDES intervention is positive then it is cost-effective compared to 
a “marginally cost-effective” program and should be selected for implementation. NHB 
findings for all outcome measures were positive, providing additional benefits to Veterans, 
supporting the case for implementation. Further, interventions that result in cost-
effectiveness ratios less than $20,000 per QALY are recommended for rapid implementation 
into healthcare systems and the HITIDES intervention certainly meets this criterion.[71]
Collaborative care approaches to depression management in primary care settings have been 
shown to be cost effective and associated with greater patient satisfaction outcomes.[3, 69] 
However, HIV clinics may be considered the patient’s medical home and may not be located 
in primary care clinics. Therefore, considering available resources, HIV clinics could obtain 
depression collaborative care from on-site resources (within the HIV clinic or a nearby 
primary care clinic) or an off-site collaborative care team used in the HITIDES study. 
Another alternative is a hybrid team with both on-site and off-site collaborative care 
resources but the hybrid team was not tested in this study. While cost savings is not a 
prerequisite for implementation of a program to improve the mental health of patients,[72] 
the impressive results from the HITIDES intervention shifts the question from whether to 
implement to how best to implement this program. The depression collaborative care 
literature supports both on-site and off-site depression care teams.[73] The HITIDES 
intervention used an off-site team to cover three specialty clinics that differed across many 
characteristics (e.g. size, location, HIV provider mix, etc.).[38] The use of a single, centrally 
located care manager whose time could be devoted solely to this intervention may enhance 
intervention fidelity and introduce efficiencies in both training and supervision costs.
This study has several limitations worth noting. First, although the VA is the largest single 
provider of HIV care in the world and largest managed care organization in the US, the 
results of this study may not be generalizable to systems of care that are less integrated or 
that do not use electronic medical records. However, as the healthcare system changes these 
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differences may be diminish. While the demographic and clinical characteristics of VA 
patients are typically different from patients in other healthcare settings, this limitation is 
less important for patients with HIV where the population differences are less prominent. 
Additionally, the DSS cost data only includes care received in the VA system. While 
comprehensive HIV care was provided to both the usual care and intervention groups in the 
study, any care received outside the VA system would not be represented in our findings. 
This would be especially concerning for an older group of study subjects with eligibility for 
both Veterans benefits and Medicare, but with an average age around 50 in this study this 
concern is diminished. The HITIDES intervention utilized an off-site intervention team; the 
relationship or generalizability of this approach to that of an on-site team is unknown. Our 
base case analysis used the DFD to QALY conversion formula that has been used in other 
depression collaborative care studies; however, there is no gold standard effectiveness 
measure for depression studies. Therefore, several QALY measures were used including the 
DFD to QALY conversion and generic QALY measures. Our results suggest that the DFD 
0.2 [conservative] to QALY conversion is more consistent with the results from generic 
QALY measures.
In conclusion, in a specialty physical health clinic this depression collaborative care 
intervention (HITIDES) was effective and cost-saving. This finding is consistent with other 
primary care depression collaborative care results in subgroups of patients with expensive 
physical health comorbidities. Implementation of off-site depression collaborative care 
programs in specialty care clinics or to targeted patients based on clinical characteristics 
may be a strategy that not only improves outcomes for patients, but also maximizes the 
efficient use of limited healthcare resources.
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Table 1
Baseline Participant Sociodemographic and Clinical Characteristics
Group
Variable Intervention (n=123) Usual Care (n=126)
Sociodemographic
Age, mean (SD), y 49.8 (8.7) 49.8 (10.5)
Male sex 120 (97.6) 122 (96.8)
African American race 78 (63.4) 77 (61.6)
Single/never married 103 (83.7) 98 (77.8)
High school graduate or higher 118 (95.9) 113 (89.7)
Annual income ≥ $20,000 60 (50.8) 52 (42.6)
Clinical
SF-12V PCS score, mean (SD) 41.5 (12.5) 39.5 (11.6)
SF-12V MCS score, mean (SD) 34.3 (10.5) 35.1 (11.0)
SCL-20 score, mean (SD) 1.8 (0.6) 1.9 (0.7)
QWB-SA score, mean (SD)** 0.49 (0.1) 0.44 (0.1)
Physical health comorbidity score, mean (SD)* 3.2 (2.3) 3.8 (2.3)
PHQ-9, mean (SD) 15.7 (4.2) 16 (4.7)
Major depression 92 (74.8) 98 (77.8)
Panic disorder 10 (8.1) 18 (14.3)
Generalized anxiety disorder 74 (60.2) 76 (60.3)
Posttraumatic stress disorder 34 (27.6) 40 (31.7)
At-risk drinking 19 (15.4) 26 (20.6)
Any inpatient mental health admission 33 (26.8) 32 (25.4)
Any past depression treatment 98 (79.7) 98 (77.8)
Any depression treatment in past 6 mos. 68 (55.7) 67 (53.2)
Depression treatment type
Watchful waiting acceptable 88 (71.5) 85 (67.5)
Antidepressant medication acceptable 88 (72.1) 87 (69.6)
Individual counseling acceptable 108 (87.8) 113 (89.7)
Group counseling acceptable 66 (53.5) 76 (60.3)
Bothersome HIV symptoms, mean (SD) 7.8 (4.1) 8 (4.3)
Current anti-HIV prescription 99 (80.5) 99 (78.6)
Skipped anti-HIV medication in past 4 d 23 (23.2) 28 (28.3)
Anti-HIV medication adherence, mean % (SD) 93.5 (16.2) 91.2 (20.1)
Current AD prescription 75 (61.0) 78 (61.9)
Skipped AD in past 4 d 22 (29.3) 20 (25.6)
AD regimen adherence, mean % (SD) 85.4 (30.5) 86.4 (31.1)
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Abbreviations: AD, antidepressant; HIV, human immunodeficiency virus; MCS, mental component summary; PCS, physical component summary; 
PHQ-9, 9-item Patient Health Questionnaire; QWB-SA, Quality of Well-Being Self-administered Scale; SCL-20, 20-item Hopkins Symptom 
Checklist; SF-12V, Medical Outcomes Study Veterans 12-Item Short-Form Health Survey.
a
Unless otherwise indicated, data are expressed as number (percentage) of participants. Percentages reflect the following missing data: race, 1 
usual care participant; annual income, 5 intervention and 4 usual care participants; any depression treatment in the past 6 months, 1 intervention 
participant; and antidepressant acceptable, 1 intervention and 1 usual care participant.
b
P .01 for intervention vs usual care.
c
P .05 for intervention vs usual care.
d
The PHQ-9 was used as depression screening measure. The SCL-20 was used as the depression outcome measure.
e
Mental health comorbidity was identified using the Mini International Neuropsychiatric Interview.
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Table 3
Adjusted Mean Incremental Cost per QALY Ratios and Net Health Benefit (Original Sample)











Depression free days (DFD 0.4 [traditional]) (fully 
depressed=0.6)a
0.020 −67,663 −26,416 0.048
Depression free days (DFD 0.2 [conservative]) 
(fully depressed=0.8)a
0.011 −125,004 −48,803 0.038
SF-12V standard gamble conversionb 0.010 −131,418 −51,307 0.038
Quality of Well-Being self-administeredc 0.009 −147,014 −57,395 0.037




Depression-free days (DFD)a 19 −71 −28 156
Costing method Cost Difference (Int-UC)
Outpatient and pharmacy ($)d −1,368
Outpatient, inpatient, and pharmacy ($)e −534
a
Case mix variables were baseline 20-item Hopkins Symptom Checklist (SCL-20) score, physical health comorbidity, HIV symptom index, marital 
status, annual household income, comorbid mental health, current HIV medication, any inpatient mental health visit and any depression treatment 
in the past 6 months
b
Case mix variables were baseline 20-item Hopkins Symptom Checklist (SCL-20) score, physical health comorbidity, HIV symptom index, 
education, annual household income, comorbid mental health, current HIV medication, any inpatient mental health visit, and any depression 
treatment in the past 6 months
c
Case mix variables were baseline 20-item Hopkins Symptom Checklist (SCL-20) score, physical health comorbidity, HIV symptom index, marital 
status, education, annual household income, comorbid mental health, current HIV medication, any inpatient mental health visit, and any depression 
treatment in the past 6 months
d
Case mix variables were baseline 20-item Hopkins Symptom Checklist (SCL-20) score, physical health comorbidity, HIV symptom index, 
gender, race, depression, PTSD, current HIV medication
e
Case mix variables were baseline 20-item Hopkins Symptom Checklist (SCL-20) score, physical health comorbidity, HIV symptom index, marital 
status, annual household income, comorbid mental health, current HIV medication, any inpatient mental health visit, and any depression treatment 
in the past 6 months
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